320 related articles for article (PubMed ID: 10598557)
21. Overview of phase I trials of multitargeted antifolate (MTA, LY231514).
Rinaldi DA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560
[TBL] [Abstract][Full Text] [Related]
22. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
Calvert H
Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
[No Abstract] [Full Text] [Related]
23. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
24. [Pemetrexed: from preclinic to clinic].
Lansiaux A; Lokiec F
Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
[TBL] [Abstract][Full Text] [Related]
25. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Scagliotti GV; Selvaggi G
Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
27. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
28. Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.
Simon M; Blatter J; Granzow C
Anticancer Res; 2007; 27(2):769-73. PubMed ID: 17465201
[TBL] [Abstract][Full Text] [Related]
29. Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
Gangjee A; Jain HD; McGuire JJ; Kisliuk RL
J Med Chem; 2004 Dec; 47(27):6730-9. PubMed ID: 15615522
[TBL] [Abstract][Full Text] [Related]
30. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
van der Wilt CL; Kuiper CM; Peters GJ
Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
[TBL] [Abstract][Full Text] [Related]
31. Pemetrexed disodium (Eli Lilly).
Norman P
Curr Opin Investig Drugs; 2001 Nov; 2(11):1611-22. PubMed ID: 11763166
[TBL] [Abstract][Full Text] [Related]
32. MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions.
Calvert H
Semin Oncol; 1999 Apr; 26(2 Suppl 6):105-8. PubMed ID: 10598564
[No Abstract] [Full Text] [Related]
33. Antifolates: the next millennium.
Allegra CJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-2. PubMed ID: 10598548
[No Abstract] [Full Text] [Related]
34. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
35. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
36. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
Cole PD; Smith AK; Kamen BA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
[TBL] [Abstract][Full Text] [Related]
37. MTA, A Novel Multitargeted Antifolate: from preclinical to phase I and beyond. Proceedings of a meeting. Ixtapa, Mexico, March 13-15, 1998.
Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-110. PubMed ID: 10610578
[No Abstract] [Full Text] [Related]
38. Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage.
Turner RN; Aherne GW; Curtin NJ
Br J Cancer; 1997; 76(10):1300-7. PubMed ID: 9374375
[TBL] [Abstract][Full Text] [Related]
39. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
Curtin NJ; Harris AL
Biochem Pharmacol; 1988 Jun; 37(11):2113-20. PubMed ID: 3377815
[TBL] [Abstract][Full Text] [Related]
40. Overview of MTA in the treatment of non-small cell lung cancer.
Postmus PE; Green MR
Semin Oncol; 1999 Feb; 26(1 Suppl 4):31-6. PubMed ID: 10201519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
